Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug Profiles
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones
Featured News & Press Releases
Jul 23, 2021: Borui’s new drug Zebetuzumab injection have been approved for clinical trials
Jul 14, 2021: New TAVALISSE data alyses to be presented at Intertiol Society on Thrombosis and Haemostasis (ISTH) 2021 Congress
Jun 29, 2021: Hengrui Pharmaceutical provides double guarantee of efficacy and safety for ITP treatment
Jun 01, 2021: Sobi at EHA virtual congress 2021: focus on use Doptelet (avatrombopag) in chronic immune thrombocytopenia
May 28, 2021: The application for clinical trial of Zuberitamab biological product of Borui biotechnology have been accepted successively
May 12, 2021: New data on rilzabrutinib to be featured at EHA 2021 Congress highlight Sanofi’s ongoing commitment to rare blood disorders
Mar 12, 2021: First patient dosed in phase 3 study with avatrombopag for treatment of ITP in children
Jun 13, 2019: Rigel to present two posters highlighting Fostamatinib at the 24th Congress of the European Hematology Association
May 16, 2019: Rigel enrolls first patient in phase 3 clinical trial of Fostamatinib Disodium Hexahydrate in warm autoimmune hemolytic anemia
Feb 11, 2019: Scottish Medicine Consortium, following an abbreviated submission has accepted romiplostim (Nplate) for restricted use within NHSScotland
Dec 03, 2018: argenx provides detailed data from phase 2 clinical trial of efgartigimod in immune thrombocytopenia
Dec 02, 2018: Real-world data show Novartis drug Revolade improves outcomes for ITP patients compared to other second-line therapies
Oct 19, 2018: Principia Biopharma announces PRN1008 receives orphan-drug desigtion from FDA for treatment of immune thrombocytopenic purpura
Jul 31, 2018: Kyowa Hakko Kirin submits application for additiol indication for Romiplostim (Recombint) for aplastic anemia in Japan
Jan 04, 2018: Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Argenx SE, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by BeiGene Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Biogen Inc, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Biotest AG, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by BioXpress Therapeutics SA, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Clover Biopharmaceuticals Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Cour Pharmaceuticals Development Co Inc, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by GC Pharma, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Generium, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco Inc, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by GlaxoSmithKline Plc, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by HanAll Biopharma Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hutchison MediPharma Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Iltoo Pharma, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by InnoCare Pharma Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by KM Biologics Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Oak Hill Bio Inc, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmagenesis Inc, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmapraxis, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by PlateletBio, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Principia Biopharma Inc, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals Inc, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Shandong Quangang Pharmaceutical Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Swedish Orphan Biovitrum AB, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Taiho Pharmaceutical Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by UCB SA, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Zhengda Tianqing Pharmaceutical Group Co Ltd, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, 2022
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, 2022 (Contd..1)
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, 2022